



MEDIGARD LIMITED

Office 14A, Tedder Terraces, 26-30 Tedder Avenue, Main Beach QLD 4217

Telephone +61 7 5528 0370; Fax +61 7 5528 0275

E-mail office@medigard.com.au www.medigard.com.au

ABN 49 090 003 044

25 November, 2009

Manager of Company Announcements
Australian Stock Exchange Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

No of pages: 22 inclusive

**ANNUAL GENERAL MEETING – CHAIRMAN AND CHIEF EXECUTIVE OFFICER
PRESENTATIONS**

The following is the address to be made by the Chairman together with a slide presentation to be made by the Chief Executive Officer. Both will occur at the Annual General Meeting of Medigard Limited this evening.

**Peter Emery
Chief Executive Officer**

**For further information contact:
Peter Emery, Telephone (07) 5528 0370**



**CHAIRMAN'S ADDRESS
TO
THE 2009 ANNUAL GENERAL MEETING
OF
MEDIGARD LIMITED**

On behalf of myself and your Board, Welcome to our sixth Annual General Meeting.

Thank you for your attendance and interest in our year's activities.

In preparing this address, I revisited the previous 5 years of having delivered such, and was reminded of the extra-ordinarily long time it has taken to get somewhere and the number of times that we seemingly had the successful outcomes that we all deserve, within reach – and so it comes to today.

Our key products have been displayed, played with, subjected to all sorts of tests, used and evaluated by some of the leading hospitals and health care centres in the USA – our prime market. These included Providence Hospital – Maryland, Washington Adventist Hospital and Georgetown Hospital. In all areas they have expressed the highest acclaim and acceptance - to a point where we are now confident that sales and distribution organisations are keen and ready to sign on and deliver volume orders. We are expecting a successful outcome to distribute will eventuate early in the New Year – thereafter the lead time necessary to establish production and embark upon sales and marketing commences.

With such in prospect it is necessary to organise supply of our products, and we have been all over the world to achieve the highest and best manufacturing arrangements. In this area

also we have been well armed with the results of our market evaluation processes and have three manufacturers interested in our business. This part of our task is the most critical as the outcome must embody high quality instruments, the security of large volume production - on time - and at a competitive cost. In most negotiations the need for us to take charge of the key tools for the manufacture has become paramount.

To this end Medigard will supply and own the dies and moulds intrinsic to our patented design. The cost of such, and the contribution required by Medigard will only be known after selection of the successful partner, at which time we expect the Company will seek a further infusion of funds. This will provide an opportunity for shareholders to participate to a greater degree in the success of the venture.

In closing, you probably know that our Board and staff are by any comparison with our Company's peers and personnel, extremely competent, dedicated, and efficient and have given me and you the shareholders the most meritorious service without complaint and for scant reward. While I thank you for your support, I also as a shareholder thank them for us.



Annual General Meeting

25 November 2009

CEO Presentation



➤ Progress



FDA approval for BCD

- Regulatory approval to market BCD in USA
- Facilitates clinical trials on live patients
- Credibility with other regulators and other markets



Product Evaluations

- 6 major USA hospitals and pathology clinics



- 95.7% agreed device required minimal training
- 97.87% agreed retraction feature easy to activate
- 78.72% agreed device safer to use than the current BCD
- 74.47% agreed they would recommend the purchase of the Medigard BCD if it cost about the same as the current BCD



Grant of US patent for BCD

- Protection for the life of the patent
- Supported by strong US Attorney opinion



FDA application for Syringe in process

- Biocompatibility testing results clear and positive
- Expected approval mid 2010



ISO 13485 accreditation application

- Quality accreditation of existing procedures
- Prelude to Canadian and other regulatory approval



➤ People



- Continuity of team
- Significant contributions
- Introductions



➤ Future Milestones



Strategic partners manufacturing and distribution

- Ongoing discussions and agreement in principle with distributors
- Impending visit to USA



Regulatory approval

- Canada, Europe, Australia and Asia for BCD
- USA, Canada, Europe, Australia and Asia for syringe



Further products

- Other versions of syringe
- Further prototypes 1 ml syringe
- Valve
- Other products in pipeline



➤ Finance



- Refer to Annual Report for 2009 results

- Capital needs
 - Tooling and equipment for BCD
 - Further product development
 - Working capital
 - Other opportunities



➤ Summary



- Continued confidence in products
- Considerable advances in marketing and manufacture setting up the next phase for the company
- Vision to expand the company building on relationships and growing the product range
- Further capital raising required to achieve goals



Questions and Discussion